Clinical Trial Update: This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure [Phase 3]

View source ↗

Summary

Phase 3 study comparing LCZ696 (sacubitril/valsartan) with Enalapril in chronic heart failure with reduced ejection fraction was terminated; results were posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Enalapril (enalapril)
• LCZ696 (sacubitril/valsartan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Heart Failure With Reduced Ejection Fraction | Phase 3 | Status: TERMINATED | Results posted: 2015-09-07